A detailed history of Siren, L.L.C. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Siren, L.L.C. holds 563,314 shares of BGNE stock, worth $102 Million. This represents 6.32% of its overall portfolio holdings.

Number of Shares
563,314
Holding current value
$102 Million
% of portfolio
6.32%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$143.93 - $224.51 $81.1 Million - $126 Million
563,314 New
563,314 $126 Billion

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Siren, L.L.C. Portfolio

Follow Siren, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Siren, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Siren, L.L.C. with notifications on news.